First-in-human clinical trials for cancer and blood disorders

In this topical collection (12 articles)

1. Correspondence

   FIT-based risk-stratification model effectively screens colorectal neoplasia and early-onset colorectal cancer in Chinese population: a nationwide multicenter prospective study

   Shengbing Zhao, Shuling Wang, Peng Pan, Tian Xia… Article:162

   Download PDF (3084KB) View Article

2. Research

   A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma

   Heng Mei, Chenggong Li, Huiwen Jiang, Xinying Zhao… Article:161

   Download PDF (8815KB) View Article

3. Letter to the Editor

   Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies

   Bo Jiang, Junyuan Qi, Yuqin Song, Zengjun Li… Article:130

   Download PDF (829KB) View Article

4. Research

   Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer

   Apostolia-Maria Tsimberidou, Jamie V. Shaw, Dejan Juric… Article:127

   Download PDF (1073KB) View Article

5. Correspondence

   Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2

   Sara Pusceddu, Francesca Corti, Natalie Prinzi… Article:119

   Download PDF (1231KB) View Article

6. Review

   Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

   Yuchen Wang, Hao Zhang, Chao Liu, Zeyu Wang, Wantao Wu… Article:111

   Download PDF (1904KB) View Article

7. Research

   Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

   Jonas S. Heitmann, Richard F. Schlenk, Daniela Dörfel… Article:96

   Download PDF (1690KB) View Article

8. Correspondence

   First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia

   Xin Jin, Meng Zhang, Rui Sun, Hairong Lyu, Xia Xiao… Article:88

   Download PDF (1951KB) View Article

9. Research

   Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study

   Pierfrancesco Tassone, Maria Teresa Di Martino… Article:68

   Download PDF (2300KB) View Article

10. Correspondence

    Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting

    Katherine W. DiNardo, Thomas W. LeBlanc, Hui Chen Article:17

    Download PDF (804KB) View Article

11. Research

    Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma

    Chenggong Li, Fen Zhou, Jing Wang, Qi Chang, Mengyi Du… Article:5

    Download PDF (3158KB) View Article

12. Review

    Vaccines: a promising therapy for myelodysplastic syndrome

    Kriti Gera, Anjali Chauhan, Paul Castillo… Article:4

    Download PDF (1523KB) View Article